Jeffrey W Tyner

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

This paper develops a domain-adversarial neural network to predict drug combination synergy in leukemia patients using bulk transcriptomics data, showing improved accuracy over existing methods.

This paper develops a rapid qPCR-based gene expression profiler to predict AML patient response to standard therapies using cell state and BCL2 family gene expression signatures.

This study shows that combining MEK and TNK2/SRC inhibitors effectively treats PTPN11-mutant leukemias in mouse models and patient-derived xenografts.

The paper characterizes age-related and inter-individual variation in circulating hematopoietic stem cells and establishes a normal reference to identify hematological disorders.